Lord, Abbett & Co
VRNA

Lord, Abbett & Co’s Verona Pharma VRNA Stock Holding History

Lord, Abbett & Co’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-653,118
Closed -$61.8M – 585
2025
Q2 		$61.8M Sell
653,118
-271,680
-29% -$20.1M 0.2% 128
2025
Q1 		$58.7M Buy
+924,798
New +$55.3M 0.21% 132

Other funds holding VRNA

PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.3B AUM 67.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Lord, Abbett & Co's VRNA Position: Q3 2025 in Review

Lord, Abbett & Co sold out of Verona Pharma (VRNA) in Q3 2025, closing a stake of 653,118 shares — an estimated $61.8M sold.

Lord, Abbett & Co first reported a position in VRNA in Q1 2025 and held it in 2 quarters. The position peaked at $61.8M in Q2 2025. 243 funds tracked by Wall St. Rank hold VRNA as of Q3 2025.

  • Lord, Abbett & Co reported no remaining Verona Pharma position as of Q3 2025 after selling out during the quarter.
  • Lord, Abbett & Co sold 653,118 Verona Pharma shares in Q3 2025, an estimated $61.8M.
  • Lord, Abbett & Co first reported a position in Verona Pharma in Q1 2025 and held it in 2 quarters.
  • Lord, Abbett & Co's Verona Pharma position peaked at $61.8M in Q2 2025.
  • 243 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2025.

Based on Lord, Abbett & Co's 13F filing for Q3 2025, filed 13 Nov 2025.